Revenue segments as reported by the company.

Medical Devices

Specialty Pharmaceuticals

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Royalty expense

Amortization expense

Intangible asset impairment charges

Contingent consideration net expense (benefit)

Restructuring net charges (credits)

Litigation-related net charges (credits)

Gain on disposal of businesses and assets

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Boston Scientific

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Boston Scientific reports solid Q4 performance and eyes global growth

Boston Scientific's Q4 performance was solid, with growth across regions and business units.
Challenges include potential sales growth hurdles in Q1 2023 and headwinds from tough comps and market adjustments.
Opportunities lie in continued momentum in key business units, successful product launches, and global growth prospects.
The company remains focused on sustaining growth, expanding margins, and delivering double-digit adjusted EPS growth.

Boston Scientific surpasses Q1 expectations, eyes growth through Farapulse

Boston Scientific's Q1 '23 earnings call showcased strong performance, with exceeding revenue expectations and solid organic sales growth. The company's strategic focus on high-growth M&A, resolving supply constraints for Farapulse, and capital allocation priorities position it well for future growth. Challenges include potential earnings dilutive deals and addressing free cash flow conversion challenges.

Boston Scientific surpasses Q2 expectations, eyes margin expansion and innovation

Boston Scientific delivered a strong Q2 '23 performance, exceeding expectations with robust sales growth and improved adjusted EPS, driven by strong performance across key regions and business segments.
While facing challenges such as inflation impact and market dynamics, the company remains focused on opportunities for margin expansion, product innovation, and strategic acquisitions to drive future growth.
With a positive outlook for the coronary business, upcoming product launches, and a commitment to operational excellence, Boston Scientific aims to maintain its competitive edge and capitalize on market opportunities.
Anticipated results from trials, market potential for new products, and a focus on sustainable growth strategies position Boston Scientific for continued success and market leadership in the healthcare sector.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities ahead

Boston Scientific's Q3 2023 results exceeded expectations, with strong performance across regions and business units.
The company raised full-year guidance, expecting organic revenue growth of approximately 11% and adjusted EPS range of $1.99 to $2.02.
Challenges in the Neuromodulation business and cost impacts are being addressed for future improvement.
Opportunities lie in acquisitions, FDA approvals, and strategic commercial initiatives for growth and margin expansion.

Boston Scientific (BSX) exceeds Q4 expectations, eyes growth opportunities

Boston Scientific (BSX) reported impressive Q4 2023 results, exceeding sales and EPS guidance.
The company showcased strong regional growth, highlighted key products, and outlined solid 2024 outlook.
While facing challenges like delayed product launches and market disruptions, BSX remains focused on growth opportunities.
Strategic acquisitions and margin improvement initiatives position Boston Scientific for continued success in the future.

Boston Scientific beats Q1 expectations, eyes growth in key markets

Boston Scientific delivered strong Q1 results, exceeding expectations and showcasing growth across key regions and business units.
While facing challenges like inventory charges, the company is focused on leveraging opportunities in expanding product indications and enhancing capabilities.
With raised full-year guidance and a focus on innovation and market expansion, Boston Scientific is poised for continued growth and success in 2024.

Boston Scientific (BSX) reports stellar Q2 results and eyes sustained growth

Boston Scientific's Q2 2024 performance exceeded expectations, showcasing strong financial results and regional sales growth across key markets.
The company's strategic strengths lie in diversified business units, innovative products like FARAPULSE, and strategic acquisitions like Silk Road Medical.
While challenges exist in adoption metrics and margin expansion, BSX's focus on reinvestment and growth opportunities position it well for sustained success.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities in Asia

Boston Scientific's Q3 performance exceeded expectations, driven by strong sales growth and increased adjusted EPS.
The company's focus on innovation and strategic investments in key business units like Cardiology and Neuromodulation bode well for future growth.
Despite challenges in China and the need to deliver on growth targets, Boston Scientific remains confident in its ability to sustain top-tier financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

MARLBOROUGH, Mass., March 3, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement with an affiliate of Baring Private Equity Asia (BPEA) to acquire the global surgical business of Lumenis LTD., a privately-held company that...

Boston Scientific Announces Agreement To Acquire Lumenis LTD. Surgical Business From Baring Private Equity Asia

Biogen

Duke Energy

GlaxoSmithKline

Las Vegas Sands

Raytheon Technologies

AT&T

The market is starting to get volatile again and sector rotation is underway. Clear the decks by dumping these stocks to sell for March.

7 Stocks to Sell for March

Henry Schein

We think that ​Henry Schein currently is a better pick compared to Boston Scientific. HSIC stock trades at about 0.9x trailing Revenues, compared to around 5.5x for Boston Scientific.

Henry Schein Likely To Offer Better Returns Compared To Boston Scientific Stock

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

Biotech stocks offer a textbook retracement pattern. The risk is low, and the reward is high.

3 Biotech Stocks to Buy As Things Heat Up for the Sector

MARLBOROUGH, Mass., Feb. 12, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On February 25, 2021, Dan Brennan, executive vice president and chief financial officer, and Susie Lisa, vice president, Investor Relations,...

Boston Scientific Announces February and March 2021 Conference Schedule

Barring MedSurg, organic revenues at each of Boston Scientific (BSX) core segments and geographies are down in Q4 but the magnitude of this decline is lower than Q3.

Boston Scientific (BSX) Hurt by Product Recall, Conversion

Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q4 2020 Results - Earnings Call Transcript

Apart from a drop in Q4 earnings and revenues drop year over year, Boston Scientific (BSX) also registers strong sequential decline in overall financial performance.

Boston Scientific (BSX) Q4 Earnings Miss, Margins Decline

Boston Scientific (BSX) delivered earnings and revenue surprises of -25.81% and -0.02%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Boston Scientific (BSX) Q4 Earnings and Revenues Lag Estimates

Shares of Boston Scientific (NYSE:BSX) fell 2.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 50.00% year over year to $0.23, which missed the estimate of $0.31.

Recap: Boston Scientific Q4 Earnings

Shares of Boston Scientific Corp. dropped 3.2% in premarket trading Wednesday, after the medical technology company reported fourth-quarter profit and revenue that fell more than expected, and provided a downbeat first-quarter outlook. Net income fell to $138 million, or 10 cents a share, from $4.00 billion, or $2.83 a share, in the year-ago period.

Boston Scientific stock falls after profit and sales miss, downbeat outlook

Boston Scientific earnings and sales fell more than expected, while the medical device maker guided low on 2021 earnings. BSX stock fell early Wednesday.

BSX Stock Falls As Boston Scientific Earnings Misses Estimates

MARLBOROUGH, Mass., Feb. 3, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a reported basis, (8.3) percent on an operational1 basis and (8.0) percent on...

Boston Scientific Announces Results For Fourth Quarter And Full Year 2020

New York, New York--(Newsfile Corp. - February 2, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Boston Scientific Corporation ("Boston Scientific") (NYSE: BSX) between April 24, 2019 and November 16, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To get...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Boston Scientific Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 2, 2021 - BSX

LOS ANGELES--(BUSINESS WIRE)---- $BSX #BSX--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Boston Scientific Corporation

DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Boston Scientific Corporation and Encourages Investors with Losses of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - February 2, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Boston Scientific investors under the federal securities laws.To join the Boston...

BSX Final Deadline Today: Rosen, National Trial Counsel, Reminds Boston Scientific Corporation Investors of Important February 2 Deadline in Securities Class Action - BSX

New York, New York--(Newsfile Corp. - February 1, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX) alleging that the Company violated federal securities laws.Class Period: April 24, 2019 and November 16, 2020Lead Plaintiff Deadline: February 2, 2021Learn more about your recoverable losses in BSX:

BSX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of February 2, 2021 in the Class Action Filed on Behalf of Boston Scientific Corporation Limited Shareholders

LOS ANGELES, Feb. 1, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Boston Scientific Corporation ("Boston Scientific" or "the Company") (NYSE: BSX) for violations of §§10(b) and 20(a) of the...

DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Boston Scientific Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NASDAQ: BSX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Boston Scientific securities between April 24, 2019 to November 16, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/bsx.

BSX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Boston Scientific Corporation Shareholders of Class Action and Lead Plaintiff Deadline: February 3, 2021

NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...

BSX FILING DEADLINE TOMORROW: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Lawsuit Against Boston Scientific Corporation

NEW YORK, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Boston Scientific investors under the federal securities laws.

BSX FINAL DEADLINE TOMORROW: ROSEN, TOP RANKED INVESTOR COUNSEL, Reminds Boston Scientific Corporation Investors of Important February 2 Deadline in Securities Class Action – BSX

NEW YORK, Jan. 31, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers. The class action, filed in United States District Court for the...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline - BSX

New York, New York--(Newsfile Corp. - January 30, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead plaintiff deadline.SO WHAT: If you purchased Boston Scientific securities during the Class Period you may be entitled to compensation without payment of any out of...

Final Deadline Notice: Rosen, Top Ranked National Investor Attorneys, Encourages Boston Scientific Corporation Investors with Large Losses to Secure Counsel Before Important Deadline - BSX

LOS ANGELES--(BUSINESS WIRE)---- $BSX #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Boston Scientific Corporation (BSX)

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Boston Scientific Corporation (BSX)

New York, New York--(Newsfile Corp. - January 28, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NASDAQ: BSX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Boston Scientific securities between April 24, 2019 to November 16, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case...

BSX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Boston Scientific Corporation Shareholders of Class Action and Lead Plaintiff Deadline: February 3, 2021

News for Boston Scientific Stock (BSX)